Clinical presentation and diagnostic delay in bullous pemphigoid: A prospective nationwide cohort

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 1111-1117

  Della Torre, R ^a   Combescure, C ^b   Cortes B ^c   Marazza, G ^d   Beltraminelli, H ^a   Naldi, L ^e   Borradori, L ^a  

^a Klinik und Poliklinik fur Dermatologie   (Switzerland)

^b Service d'Epidemiologie Clinique   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLISTER; BULLOUS PEMPHIGOID; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; DELAYED DIAGNOSIS; ECZEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SWITZERLAND; SYMPTOMATOLOGY; URTICARIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COHORT STUDIES; DELAYED DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SWITZERLAND; TIME FACTORS; YOUNG ADULT;

EID: 84868099795     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11108.x     Document Type: Article

References (35)

1. Labib RS, Anhalt GJ, Patel HP, et al. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986; 136: 1231-5.
2. Stanley JR, Tanaka T, Mueller S, et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988; 82: 1864-70.
3. Sawamura D, Li K, Chu ML, et al. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 1991; 266: 17784-90.
4. Stanley JR,. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 1993; 53: 291-325.
5. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92: 2480-8.
6. Nishie W, Sawamura D, Goto M, et al. Humanization of autoantigen. Nat Med 2007; 13: 378-83.
7. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48-52.
8. Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 1999; 41: 266-8.
9. Marazza G, Pham HC, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861-8.
10. Bertram F, Brocker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 434-40.
11. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
12. Joly P, Baricault S, Sparsa A, et al,. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132: 1998-2004.
13. Di Zenzo G, Marazza G, Borradori L,. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol 2007; 23: 257-88.
14. Schmidt E, della Torre R, Borradori L,. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29: 427-38, iii- ix.
15. Liu HN, Su WP, Rogers RS 3rd,. Clinical variants of pemphigoid. Int J Dermatol 1986; 25: 17-27.
16. Korman N,. Bullous pemphigoid. J Am Acad Dermatol 1987; 16: 907-24.
17. Castanet J, Lacour JP, Ortonne JP,. [Atypical clinical forms of bullous pemphigoid]. Ann Dermatol Venereol 1990; 117: 73-82 (in French).
18. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134: 465-9.
19. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141: 691-8.
20. Cortés B, Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 2011; 165: 368-74.
21. Sneddon IB, Church R,. Diagnosis and treatment of pemphigoid; report on 22 cases. Br Med J 1955; 2: 1360-3.
22. Bean SF, Cox GF,. Bullous diseases in the elderly. Geriatrics 1980; 35: 95-9.
23. Asbrink E, Hovmark A,. Clinical variations in bullous pemphigoid with respect to early symptoms. Acta Derm Venereol 1981; 61: 417-21.
24. Amato DA, Silverstein J, Zitelli J,. The prodrome of bullous pemphigoid. Int J Dermatol 1988; 27: 560-3.
25. Lamb PM, Abell E, Tharp M, et al. Prodromal bullous pemphigoid. Int J Dermatol 2006; 45: 209-14.
26. Alonso-Llamazares J, Rogers RS 3rd, Oursler JR, et al. Bullous pemphigoid presenting as generalized pruritus: observations in six patients. Int J Dermatol 1998; 37: 508-14.
27. Nakatani T, Inaoki M, Takehara K,. Bullous pemphigoid with a prolonged prodrome. J Dermatol 2008; 35: 433-6.
28. Rieckhoff-Cantoni L, Bernard P, Didierjean L, et al. Frequency of bullous pemphigoid-like antibodies as detected by western immunoblot analysis in pruritic dermatoses. Arch Dermatol 1992; 128: 791-4.
29. Hofmann SC, Tamm K, Hertl M, et al. Diagnostic value of an enzyme-linked immunosorbent assay using BP180 recombinant proteins in elderly patients with pruritic skin disorders. Br J Dermatol 2003; 149: 910-12.
30. Vaillant L, Bernard P, Joly P, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol 1998; 134: 1075-80.
31. Joly P, Courville P, Lok C, et al. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology 2004; 208: 16-20.
32. Ingen-Housz-Oro S, Roujeau JC, Ferranti V, et al,. [Factors associated with delayed diagnosis of bullous pemphigoid]. Ann Dermatol Venereol 2009; 136: 696-701 (in French).
33. Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008; 128: 415-26.
34. Bernard P, Reguiai Z, Tancrede-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009; 145: 537-42.
35. Langan SM, Groves RW, West J,. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131: 631-6.